Noile-Immune Biotech Inc. Logo

Noile-Immune Biotech Inc.

Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.

4893 | T

Overview

Corporate Details

ISIN(s):
JP3759560000
LEI:
Country:
Japan
Address:
港区芝大門二丁目12番10号
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Noile-Immune Biotech Inc. is a clinical-stage biotechnology company focused on the development and commercialization of novel cancer immunotherapies. The company specializes in CAR-T cell therapy aimed at treating solid tumors, a significant challenge in oncology. Its core is the proprietary PRIME (Proliferation-Inducing and Migration-Enhancing) technology, a next-generation platform designed to augment the efficacy of CAR-T cells. Noile-Immune advances its therapeutic pipeline through in-house research and strategic partnerships with academic and corporate entities, with the mission to create transformative treatments for cancer patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-08 09:15
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-08-08 09:14
Interim Report
半期報告書-第11期(2025/01/01-2025/12/31)
Japanese 143.9 KB
2025-04-01 09:11
Post-Annual General Meeting Information
臨時報告書
Japanese 23.5 KB
2025-03-28 05:44
Registration Form
確認書
Japanese 8.2 KB
2025-03-28 05:43
Governance Information
内部統制報告書-第10期(2024/01/01-2024/12/31)
Japanese 21.2 KB
2025-03-28 05:42
Annual Report
有価証券報告書-第10期(2024/01/01-2024/12/31)
Japanese 4.1 MB
2024-10-15 05:07
Report Publication Announcement
訂正確認書
Japanese 8.2 KB
2024-10-15 05:06
Interim Report
訂正半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 124.4 KB
2024-08-13 05:02
Interim Report
半期報告書-第10期(2024/01/01-2024/12/31)
Japanese 150.3 KB
2024-08-13 05:00
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:07
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-05-14 10:05
Quarterly Report
四半期報告書-第10期第1四半期(2024/01/01-2024/03/31)
Japanese 117.7 KB
2024-04-02 06:49
Post-Annual General Meeting Information
臨時報告書
Japanese 22.2 KB
2024-03-29 06:19
Registration Form
確認書
Japanese 8.2 KB
2024-03-29 06:18
Governance Information
内部統制報告書-第9期(2023/01/01-2023/12/31)
Japanese 21.2 KB

Automate Your Workflow. Get a real-time feed of all Noile-Immune Biotech Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Noile-Immune Biotech Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Noile-Immune Biotech Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MATCHING SERVICE JAPAN CO.,LTD. Logo
Specialized recruitment firm connecting legal, finance, and accounting experts with top companies.
Japan
6539
Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU

Talk to a Data Expert

Have a question? We'll get back to you promptly.